489 related articles for article (PubMed ID: 26564155)
1. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
Tanaka S; Ninomiya T; Katafuchi R; Masutani K; Nagata M; Tsuchimoto A; Hirakata H; Kitazono T; Tsuruya K
Clin Exp Nephrol; 2016 Oct; 20(5):689-698. PubMed ID: 26564155
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
Ferraro PM; Ferraccioli GF; Gambaro G; Fulignati P; Costanzi S
Nephrol Dial Transplant; 2009 Jan; 24(1):156-60. PubMed ID: 18685141
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.
Chen J; Liu S; Xu H; Wang W; Xie Y; Tang W; Yuan Q; Zheng L; Lin L; Fu S; Shen J
Med Sci Monit; 2020 Aug; 26():e922839. PubMed ID: 32822333
[TBL] [Abstract][Full Text] [Related]
4. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
5. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
[TBL] [Abstract][Full Text] [Related]
6. Primary IgA nephropathy in elderly patients.
Cheungpasitporn W; Nasr SH; Thongprayoon C; Mao MA; Qian Q
Nephrology (Carlton); 2015 Jun; 20(6):419-25. PubMed ID: 25726845
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy.
Tanaka S; Ninomiya T; Katafuchi R; Masutani K; Tsuchimoto A; Noguchi H; Hirakata H; Tsuruya K; Kitazono T
Clin J Am Soc Nephrol; 2013 Dec; 8(12):2082-90. PubMed ID: 24178970
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
Soleymanian T; Najafi I; Salimi BH; Broomand B
Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
[TBL] [Abstract][Full Text] [Related]
9. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.
Kwok T; Leung J; Barrett-Connor E;
Age Ageing; 2017 Jan; 46(1):57-64. PubMed ID: 28181652
[TBL] [Abstract][Full Text] [Related]
10. Intrarenal Arterial Lesions Are Associated with Higher Blood Pressure, Reduced Renal Function and Poorer Renal Outcomes in Patients with IgA Nephropathy.
Zhang Y; Sun L; Zhou S; Xu Q; Xu Q; Liu D; Liu L; Hu R; Quan S; Xing G
Kidney Blood Press Res; 2018; 43(2):639-650. PubMed ID: 29698975
[TBL] [Abstract][Full Text] [Related]
11. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
Riispere Ž; Kuudeberg A; Seppet E; Sepp K; Ilmoja M; Luman M; Kõlvald K; Auerbach A; Ots-Rosenberg M
BMC Nephrol; 2017 Mar; 18(1):89. PubMed ID: 28292274
[TBL] [Abstract][Full Text] [Related]
12. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.
Bazzi C; Rizza V; Casellato D; Stivali G; Rachele G; Napodano P; Olivieri G; Gallieni M; D'Amico G
J Nephrol; 2012; 25(5):810-8. PubMed ID: 22252844
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Progression in IgA Nephropathy in Childhood.
Mizerska-Wasiak M; Małdyk J; Turczyn A; Cichoń-Kawa K; Rybi-Szumińska A; Wasilewska A; Bieniaś B; Zajączkowska M; Miklaszewska M; Pietrzyk J; Demkow U; Roszkowska-Blaim M; Pańczyk-Tomaszewska M
Adv Exp Med Biol; 2017; 955():65-73. PubMed ID: 27718216
[TBL] [Abstract][Full Text] [Related]
14. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.
Omae K; Ogawa T; Nitta K
Heart Vessels; 2010 May; 25(3):203-8. PubMed ID: 20512447
[TBL] [Abstract][Full Text] [Related]
16. Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.
Wu PC; Wu CJ; Lin CJ; Pan CF; Chen CY; Huang TM; Wu CH; Lin SL; Chen YM; Chen L; Wu VC; ;
Clin Pharmacol Ther; 2015 Oct; 98(4):442-9. PubMed ID: 26082272
[TBL] [Abstract][Full Text] [Related]
17. The effects of cytotoxic therapy in progressive IgA nephropathy.
Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
[TBL] [Abstract][Full Text] [Related]
18. Comparison of oral steroids with tonsillectomy plus steroid pulse therapy in patients with IgA nephropathy.
Hoshino Y; Moriyama T; Uchida K; Tsuchiya K; Nitta K
Clin Exp Nephrol; 2017 Aug; 21(4):617-623. PubMed ID: 27549901
[TBL] [Abstract][Full Text] [Related]
19. The beneficial effects of renin-angiotensin system blockades on 2 year outcomes in coronary artery ectasia patients.
Wang Y; Wang Y; Yin D; Dou K; Wu Y; Song W
Curr Med Res Opin; 2017 Sep; 33(9):1677-1684. PubMed ID: 28598221
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.
Tesar V; Troyanov S; Bellur S; Verhave JC; Cook HT; Feehally J; Roberts IS; Cattran D; Coppo R;
J Am Soc Nephrol; 2015 Sep; 26(9):2248-58. PubMed ID: 25677392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
